Your browser is no longer supported. Please, upgrade your browser.
Settings
STOK [NASD]
Stoke Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own0.60% Shs Outstand35.09M Perf Week-10.01%
Market Cap1.21B Forward P/E- EPS next Y-2.13 Insider Trans168.98% Shs Float34.57M Perf Month-39.36%
Income-52.20M PEG- EPS next Q-0.44 Inst Own- Short Float9.14% Perf Quarter-52.68%
Sales- P/S- EPS this Y-46.10% Inst Trans11.32% Short Ratio18.61 Perf Half Y-19.90%
Book/sh8.15 P/B3.79 EPS next Y-17.00% ROA-22.50% Target Price- Perf Year36.23%
Cash/sh7.36 P/C4.20 EPS next 5Y- ROE-23.30% 52W Range19.00 - 71.58 Perf YTD-50.09%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.82% Beta-
Dividend %- Quick Ratio25.70 Sales past 5Y- Gross Margin- 52W Low62.68% ATR3.00
Employees79 Current Ratio25.70 Sales Q/Q- Oper. Margin- RSI (14)24.60 Volatility7.14% 7.88%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.60% Profit Margin- Rel Volume0.72 Prev Close32.91
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume169.86K Price30.91
Recom2.00 SMA20-19.47% SMA50-38.54% SMA200-28.22% Volume122,971 Change-6.08%
Feb-10-21Downgrade Wedbush Outperform → Neutral
Dec-15-20Resumed H.C. Wainwright Buy $70
Dec-11-20Reiterated Needham Buy $48 → $56
Oct-23-20Initiated Cantor Fitzgerald Overweight $49
Sep-29-20Resumed JP Morgan Neutral $34
Sep-29-20Initiated Needham Buy $42
Dec-18-19Initiated Wedbush Outperform $31
Nov-12-19Initiated BTIG Research Buy $46
Oct-25-19Initiated H.C. Wainwright Buy $30
Jul-15-19Initiated JP Morgan Overweight $34
Jul-15-19Initiated Credit Suisse Outperform $35
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $44
Mar-30-21 07:30AM  
Mar-24-21 07:30AM  
Mar-15-21 09:39AM  
Mar-09-21 09:31AM  
07:30AM  
Mar-04-21 07:30AM  
Feb-26-21 06:15AM  
06:00AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Jan-22-21 08:00AM  
Jan-19-21 08:00AM  
Jan-06-21 08:00AM  
Jan-05-21 10:00AM  
Jan-04-21 04:05PM  
Dec-25-20 03:06AM  
Dec-17-20 08:00AM  
Dec-10-20 10:33PM  
Dec-04-20 04:05PM  
09:57AM  
Dec-02-20 04:05PM  
Nov-30-20 08:00AM  
Nov-25-20 07:30AM  
Nov-24-20 04:01PM  
Nov-19-20 07:00PM  
08:17AM  
Nov-18-20 04:02PM  
Nov-12-20 07:38AM  
Nov-11-20 09:00AM  
Nov-10-20 06:37AM  
Nov-09-20 07:30AM  
07:30AM  
06:15AM  
06:00AM  
Nov-05-20 10:51AM  
Nov-04-20 08:00AM  
Nov-02-20 08:00AM  
07:30AM  
Oct-14-20 05:05PM  
Oct-08-20 07:52AM  
Oct-07-20 07:00AM  
Sep-29-20 12:23PM  
09:50AM  
Sep-21-20 12:41PM  
Sep-17-20 06:00AM  
Sep-15-20 03:41PM  
11:48AM  
Sep-10-20 08:00AM  
Sep-09-20 07:30AM  
Sep-03-20 08:00AM  
Sep-02-20 04:05PM  
Aug-31-20 08:00AM  
Aug-26-20 02:00PM  
Aug-17-20 07:30AM  
Aug-11-20 12:25PM  
08:00AM  
Aug-10-20 07:30AM  
Aug-07-20 06:00AM  
Aug-04-20 12:19PM  
08:00AM  
07:30AM  
Jul-31-20 08:00AM  
Jul-09-20 05:40AM  
Jul-08-20 04:15PM  
Jun-24-20 12:27PM  
Jun-04-20 08:00AM  
May-15-20 07:00AM  
May-12-20 08:00AM  
Mar-23-20 08:00AM  
Feb-24-20 08:00AM  
Jan-08-20 07:30AM  
Jan-07-20 08:30AM  
Dec-23-19 08:30AM  
Dec-19-19 04:51PM  
Dec-08-19 10:00AM  
Dec-07-19 12:00PM  
Dec-06-19 02:23PM  
Nov-26-19 08:30AM  
08:30AM  
Nov-25-19 11:00AM  
11:00AM  
Nov-22-19 06:43AM  
Nov-12-19 08:00AM  
Nov-05-19 08:30AM  
Oct-28-19 02:12PM  
Oct-16-19 08:30AM  
Sep-30-19 08:30AM  
Sep-20-19 11:47AM  
Sep-11-19 08:00AM  
Aug-29-19 09:16PM  
Aug-21-19 07:40AM  
Aug-20-19 08:00AM  
Aug-14-19 08:00AM  
Aug-06-19 01:39PM  
Jun-21-19 04:01PM  
Jun-19-19 11:29AM  
10:50AM  
07:51AM  
Jun-18-19 06:45PM  
08:12AM  
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Liau GeneEVP Research & Preclinical DevMar 02Option Exercise0.605,1953,11726,546Mar 04 05:00 PM
Liau GeneEVP Research & Preclinical DevMar 02Sale63.055,195327,54621,351Mar 04 05:00 PM
LEVIN ARTHUR ADirectorMar 01Option Exercise0.5312,5006,57612,500Mar 03 05:10 PM
LEVIN ARTHUR ADirectorMar 01Sale60.7912,500759,8410Mar 03 05:10 PM
Tulipano Stephen JCFOFeb 23Option Exercise4.485,00022,4005,602Feb 24 05:15 PM
Tulipano Stephen JCFOFeb 23Sale58.605,000292,992602Feb 24 05:15 PM
Tulipano Stephen JCFOFeb 22Option Exercise4.4825,000112,00025,602Feb 24 05:15 PM
Tulipano Stephen JCFOFeb 22Sale58.9225,0001,472,904602Feb 24 05:15 PM
TZIANABOS ARTHURDirectorFeb 19Option Exercise2.1910,00021,90010,000Feb 23 05:28 PM
TZIANABOS ARTHURDirectorFeb 19Sale60.6710,000606,6520Feb 23 05:28 PM
Nash Huw M.COO & CBOJan 06Sale57.14321,8280Jan 06 05:26 PM
Nash Huw M.COO & CBOJan 04Option Exercise2.195,70012,4835,732Jan 06 05:26 PM
Nash Huw M.COO & CBOJan 04Sale58.975,700336,15732Jan 06 05:26 PM
Kaye Edward M. MDCEODec 30Option Exercise0.6010,0006,00010,000Jan 04 06:33 PM
Liau GeneEVP Research & Preclinical DevDec 28Option Exercise0.608,0004,80021,500Mar 04 05:00 PM
Liau GeneEVP Research & Preclinical DevDec 28Sale58.731498,75121,351Mar 04 05:00 PM
Ticho BarryChief Medical OfficerDec 21Option Exercise2.191,3652,989174,767Dec 21 04:53 PM
Ticho BarryChief Medical OfficerDec 21Sale57.621,36578,654173,402Dec 21 04:53 PM
Nash Huw M.COO & CBODec 18Option Exercise0.608,0154,8098,015Dec 18 09:08 PM
Kaye Edward M. MDCEODec 18Sale60.005,194311,6400Dec 18 09:07 PM
Nash Huw M.COO & CBODec 18Sale60.008,015480,9000Dec 18 09:08 PM
Nash Huw M.COO & CBODec 17Option Exercise0.6041,98525,19141,985Dec 18 09:08 PM
Kaye Edward M. MDCEODec 17Sale60.0019,8061,188,3605,194Dec 18 09:07 PM
Nash Huw M.COO & CBODec 17Sale60.0041,9852,519,1000Dec 18 09:08 PM
Nash Huw M.COO & CBODec 01Option Exercise2.195,70012,4835,700Dec 03 06:00 PM
Nash Huw M.COO & CBODec 01Sale49.845,700284,0800Dec 03 06:00 PM
Kaye Edward M. MDCEONov 27Sale50.0012,152607,60025,000Nov 30 05:11 PM
Kaye Edward M. MDCEONov 25Sale50.0012,848642,40037,152Nov 25 05:16 PM
Harrison Seth LoringDirectorNov 24Buy39.00375,00014,625,00017,161,713Nov 25 05:03 PM
Apple Tree Partners IV, L.P.10% OwnerNov 24Buy39.00375,00014,625,00017,161,713Nov 25 05:01 PM
TZIANABOS ARTHURDirectorNov 23Option Exercise2.1920,00043,80020,000Nov 25 05:09 PM
TZIANABOS ARTHURDirectorNov 23Sale46.0320,000920,5660Nov 25 05:09 PM
Nash Huw M.COO & CBONov 10Option Exercise1.0350,00051,32850,000Nov 10 05:42 PM
Nash Huw M.COO & CBONov 10Sale45.0050,0002,250,0000Nov 10 05:42 PM
Tulipano Stephen JCFONov 04Option Exercise4.4833,268149,04133,870Nov 04 05:31 PM
Tulipano Stephen JCFONov 04Sale40.8033,2681,357,210602Nov 04 05:31 PM
Tulipano Stephen JCFONov 03Option Exercise4.481,7327,7592,334Nov 04 05:31 PM
Tulipano Stephen JCFONov 03Sale39.841,73268,998602Nov 04 05:31 PM
Nash Huw M.COO & CBONov 02Option Exercise2.195,70012,4835,700Nov 04 05:30 PM
Tulipano Stephen JCFONov 02Option Exercise4.4835,000156,80035,602Nov 04 05:31 PM
Tulipano Stephen JCFONov 02Sale37.2535,0001,303,731602Nov 04 05:31 PM
Nash Huw M.COO & CBONov 02Sale37.215,700212,1100Nov 04 05:30 PM
Liau GeneEVP Research & Preclinical DevOct 19Option Exercise0.6732,00021,59045,500Oct 20 04:52 PM
Liau GeneEVP Research & Preclinical DevOct 19Sale37.8232,0001,210,16413,500Oct 20 04:52 PM
Liau GeneEVP Research & Preclinical DevOct 16Option Exercise0.605,8513,51119,351Oct 20 04:52 PM
Liau GeneEVP Research & Preclinical DevOct 16Sale40.005,851234,04213,500Oct 20 04:52 PM
Liau GeneEVP Research & Preclinical DevOct 13Option Exercise0.601,64998915,149Oct 13 05:43 PM
Liau GeneEVP Research & Preclinical DevOct 13Sale40.001,64965,96013,500Oct 13 05:43 PM
Nash Huw M.COO & CBOOct 01Option Exercise2.195,70012,4835,700Oct 05 05:12 PM
Nash Huw M.COO & CBOOct 01Sale34.545,700196,9010Oct 05 05:12 PM
Nash Huw M.COO & CBOSep 09Option Exercise2.1917,20137,67017,201Sep 10 06:21 PM
Nash Huw M.COO & CBOSep 09Sale30.0017,201516,0300Sep 10 06:21 PM
Nash Huw M.COO & CBOSep 08Option Exercise2.1930,71867,27230,718Sep 10 06:21 PM
Nash Huw M.COO & CBOSep 08Sale30.0030,718921,5400Sep 10 06:21 PM
Nash Huw M.COO & CBOSep 01Option Exercise2.195,70012,4835,700Sep 03 06:35 PM
Nash Huw M.COO & CBOSep 01Sale27.745,700158,1130Sep 03 06:35 PM
Nash Huw M.COO & CBOAug 28Option Exercise2.192,0814,5572,081Aug 31 06:04 PM
Nash Huw M.COO & CBOAug 28Sale30.002,08162,4300Aug 31 06:04 PM
Nash Huw M.COO & CBOAug 03Option Exercise2.195,70012,4835,700Aug 04 04:59 PM
Nash Huw M.COO & CBOAug 03Sale24.735,700140,9430Aug 04 04:59 PM
Nash Huw M.COO & CBOJul 16Option Exercise2.191,9004,1611,900Jul 17 06:02 PM
Nash Huw M.COO & CBOJul 16Sale25.061,90047,6140Jul 17 06:02 PM
Walker Robin A.Chief Legal Officer, CCO & SecJul 07Sale22.5094121,1720Jul 09 05:43 PM
Nash Huw M.COO & CBOJul 07Sale22.4191320,4570Jul 09 05:41 PM
Nash Huw M.COO & CBOJul 01Option Exercise2.193,8008,3223,800Jul 02 06:08 PM
Nash Huw M.COO & CBOJul 01Sale23.153,80087,9680Jul 02 06:08 PM
Nash Huw M.COO & CBOJun 01Option Exercise2.192,1074,6142,107Jun 03 04:55 PM
Liau GeneEVP Research & Preclinical DevJun 01Option Exercise2.1920,00043,80033,500Jun 03 04:57 PM
Ticho BarryChief Medical OfficerJun 01Option Exercise0.99174,027172,595174,027Jun 03 04:58 PM
Ticho BarryChief Medical OfficerJun 01Sale27.391,36537,387172,662Jun 03 04:58 PM
Liau GeneEVP Research & Preclinical DevJun 01Sale26.3520,000527,03713,500Jun 03 04:57 PM
Nash Huw M.COO & CBOJun 01Sale27.182,10757,2630Jun 03 04:55 PM
Liau GeneEVP Research & Preclinical DevMay 22Option Exercise0.607,5004,50021,000May 26 05:58 PM
Liau GeneEVP Research & Preclinical DevMay 22Sale30.007,500225,00013,500May 26 05:58 PM